<DOC>
	<DOCNO>NCT00331695</DOCNO>
	<brief_summary>To demonstrate intramuscular administration 17 alpha hydroxyprogesterones caproate allow reduce risk preterm delivery , 3 high risk population define association ultrasonographic cervical length egal inferiority 26 mm 20 32 week gestation : - either first episode preterm labor stop acute tocolysis ; - either history late miscarriage premature delivery uterine malformation DES - either twin pregnancy . Therefore , randomise , multicentre trial design initial stratification accord three risk group , open two parallel arm .</brief_summary>
	<brief_title>Efficacy 17 Alpha-hydroxyprogesterones Caproate Prevention Preterm Delivery</brief_title>
	<detailed_description>Objective To demonstrate intramuscular administration 17 alpha - hydroxyprogesterones caproate allows reduce risk preterm delivery , 3 high risk population define association ultrasonographic cervical length 26 mm 20 32 week gestation : - either first episode preterm labor stop acute tocolysis ; - either history late miscarriage premature delivery uterine malformation DES - either twin pregnancy . Experimental design Prospective , randomize , multicenter , trial initial stratification accord three risk group , open two parallel arm . The maximal duration treatment 16 week include patient . The duration inclusion 30 month . The duration participation patient 10 22 week . The foreseen inclusion period trial 06/01/2006 12/31/2008 Description Two therapeutic strategy compare risk group attribute uniform randomisation . Arm A : IM injection 17 alpha hydroxyprogesterones caproate , 500 mg , twice week 36 W preterm delivery high risk symptomatic group high risk twin pregnancy group . IM injection 17 alpha-hydroxyprogesterones caproate , 500 mg , week 36 W preterm delivery high risk asymptomatic group . Arm B : No treatment 17 alpha-hydroxyprogesterones caproate . ( usual management ) Presentation : Progesterone retard Pharlon 500 mg Tolerance criterion - nausea , vomit , - weakness</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>17-alpha-hydroxy-progesterone caproate</mesh_term>
	<mesh_term>11-hydroxyprogesterone</mesh_term>
	<criteria>ultrasonographic cervical length 26 mm 20 32 week gestation : either first episode preterm labor stop acute tocolysis either history late miscarriage premature delivery uterine malformation DES ; either twin pregnancy . cervical dilatation &gt; 3 cm , chorioamnionitis , fetal distress , placenta praevia , abruptio placenta , preterm premature rupture membrane , polyhydramnios , Twintwin transfusion syndrome , IUGR , preeclampsia hypertension , pathology justify preterm delivery , epilepsy drug participation another therapeutic trial , patient inform consent obtain .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Progesterone</keyword>
	<keyword>Preterm delivery</keyword>
	<keyword>Preterm labor</keyword>
	<keyword>Cervical length</keyword>
	<keyword>ultrasonography</keyword>
</DOC>